Cochrane · systematic review · CD009159
Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults
Chakupurakal, G, Freudenberger, P, Skoetz, N, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 4 · 57.1%High 2 · 28.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsATG for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation
Population: patients after allogeneic stem cell or bone marrow transplantation
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (at 36 months) | HR 0.93 [0.77, 1.13] | 9 studies · 1249 participants | Moderate Downgraded: imprecision |
Acute GVHD II to IV (90 days) | RR 0.68 [0.6, 0.79] | 10 studies · 1413 participants | High |
Overall Chronic GVHD (up to 36 months) | RR 0.53 [0.45, 0.61] | 8 studies · 1273 participants | High |
Incidence of relapse (up to 36 months) | RR 1.21 [0.99, 1.49] | 8 studies · 1315 participants | Moderate Downgraded: imprecision |
Non‐relapse mortality (at 36 months) | HR 0.86 [0.67, 1.11] | 9 studies · 1370 participants | Moderate Downgraded: imprecision |
Graft failure (during study) | RR 1.55 [0.54, 4.44] | 8 studies · 1240 participants | Low Downgraded: imprecision |
Adverse Events (during study) | no estimate extracted | 4 studies · 543 participants | Moderate Downgraded: inconsistency |